London Markets Face Mixed Signals as AstraZeneca Trial Disappointment Weighs on Investors
FTSE 100 held back by AstraZeneca – European equities presented a complex picture on Thursday as investors navigated conflicting signals from pharmaceutical developments and geopolitical tensions. While mining companies benefited from surging commodity prices, AstraZeneca’s disappointing clinical trial results cast a shadow over London’s benchmark index, causing it to lag behind continental counterparts.
FTSE Performance and Pharmaceutical Setback
The FTSE 100 index finished the trading session with a modest decline of 16.59 points, representing a 0.2% drop to close at 10,472.45. This underperformance came despite positive momentum in other sectors. Meanwhile, the FTSE 250 demonstrated stronger resilience, gaining 222.92 points or 1.0% to reach 23,240.56. The smaller-cap focused AIM All-Share also posted gains, rising 4.18 points by 0.6% to finish at 762.25.
The primary drag on London markets originated from pharmaceutical giant AstraZeneca, which experienced a sharp 6.2% decline. The company announced that Wainua, an experimental cardiovascular treatment being developed alongside Ionis Pharmaceuticals, failed to achieve its primary objective during a phase three clinical study. The medication, scientifically known as eplontersen, targets individuals suffering from transthyretin-mediated amyloid cardiomyopathy.
According to AstraZeneca’s statement, the drug did not demonstrate sufficient efficacy regarding mortality rates or cardiovascular clinical occurrences within the 140-week observation period when compared against patients receiving a placebo treatment.
“The failure does put (net present value) at risk of course, but the bigger issue is probably a degree of credibility loss with management being very confident in the trial’s ability to hit the primary endpoint,” noted Jefferies analyst Michael Leuchten.
Market expectations suggest JPMorgan analyst Richard Vosser believes consensus will now eliminate most of the $3.3 billion risk-adjusted peak sales projection previously assigned to Wainua.
Commodity Rally and International Markets
The AstraZeneca decline was partially counterbalanced by robust performance in mining equities as metal prices experienced significant rallies. Antofagasta shares climbed 5.4%, Anglo American advanced 5.8%, and Glencore rose 4.2%, making them among the most prominent gainers on the London exchange.
Commodity markets showed considerable strength throughout the session. Gold prices reached $4,126.64 per ounce on Thursday, marking an increase from Wednesday’s level of $4,022.15. Silver appreciated by 3.5% while copper gained 2.7% during the same trading day.
Across the Atlantic, European equity markets mirrored positive sentiment. The CAC 40 in Paris concluded with a 0.9% gain, matching the performance of the DAX 40 in Frankfurt. American indices also posted modest advances, with the Dow Jones Industrial Average rising 0.3%, the S&P 500 climbing 0.6%, and the Nasdaq Composite advancing 0.7%.
Corporate Earnings and Geopolitical Developments
PepsiCo experienced a 3.5% share price reduction following the release of mixed second-quarter financial results. The multinational food and beverage corporation reported attributable net income of $2.98 billion for the quarter ending June 13, more than doubling from the $1.26 billion recorded during the same period a year earlier. Net revenue expanded 6.4% to $24.18 billion compared to $22.73 billion previously, though organic revenue growth of 2.4% fell slightly short of the 2.6% market consensus.
Citigroup provided commentary noting that North American operations delivered softer-than-anticipated results while international organic sales growth exceeded expectations.
Oil markets softened despite renewed military confrontations between the United States and Iran. President Donald Trump expressed confidence that the latest escalation would resolve swiftly and indicated openness to additional diplomatic discussions. He further suggested that Tehran desired “to make a deal so badly.”
“After spooking markets yesterday by saying the ceasefire with Iran is over, President Trump has now claimed that Iran wants to make a deal, although this has not been confirmed by Tehran,” explained Kathleen Brooks, research director at XTB.
Brent crude for September delivery declined to $77.03 per barrel on Thursday, down from Wednesday’s $80 level.
Currency and Bond Markets
Foreign exchange markets showed movement across major pairs. The euro strengthened against the US dollar, trading at 1.1432 on Thursday compared to 1.1398 on Wednesday. The dollar weakened against the yen, moving to 162.37 yen from 162.68 yen. The pound appreciated to 1.3397 dollars on Thursday afternoon from 1.3358 dollars on Wednesday, while sterling eased slightly against the euro to 1.1717 euros from 1.1722 euros.
Government bond yields contracted modestly. The US 10-year Treasury yield narrowed to 4.55% from 4.60%, and the 30-year Treasury yield decreased to 5.06% from 5.09%.
Back in London, Computacenter shares surged 7.2% after the technology services provider indicated it anticipates full-year results “comfortably ahead of market expectations,” driven by robust second-quarter trading performance. The Hatfield-based company reported that results for the three months through June exceeded internal projections, building upon what it described as an “excellent” first quarter. North American operations received particular encouragement from “even stronger-than-expected” volume growth with hyperscaler customers.
